Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1991-07-03
2000-05-30
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 8, 514 23, 536 22, 536 53, 536 88, 536123, A61K 31715, C08B 3700
Patent
active
060691352
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
The invention relates to, formulations suitable for use to treat conditions and disease, (for example cancer), the use of such formulations to treat conditions and disease, methods of treating conditions and disease, and the delivery of medicinal and therapeutic agents for the treatment of disease and conditions.
BACKGROUND OF THE INVENTION
In an article entitled "Solid cores of tumors keeping out best drugs" by Sandra Blakeslee published in the Jul. 8, 1989 edition of the Globe and Mail, Toronto, Ontario, Ms. Blakeslee submitted that a growing number of researchers believe that a basic misunderstanding of the structure of solid tumors has led researchers into designing cancer drugs that are doomed to fail in many patients.
She relates that, Dr. Herberman, Director of the Pittsburgh Cancer Center, said that for decades, cancer researchers have simply developed drugs, put them in the bloodstream and assumed they would be carried to the tumor giving almost no consideration to how uniformly the drug is distributed once it reaches the tumor.
Her article also provided that according to Dr. Judah Folkman, a leading researcher on blood growth factors at the Harvard Medical School, for a long time, physicians have been taught that tumors outgrow their blood supply. According to the article that statement is not true. Tumors compress their blood supply. This compression makes it harder to administer drugs.
The article provides further that most people think a tumor is nothing but a collection of cancer cells. According to Dr. Jain, another researcher, in reality the tumor is only 50 percent cells. The other half is blood vessels and interstitial space. Interstitial space in a tumor, he said, can be likened to the space between marbles packed in a box.
The article further provides that no matter how biological agents are mixed and administered, they must cross a blood-vessel wall and then cross the interstitium to reach their targets, cancer cells. The article continues that every tumor is different and there are different regions within each. Moreover, tumors change daily as they grow and rearrange parts. Most blood vessels inside tumors are highly disorganized as they take tortuous turns and grow peculiar attachments to nearby vessels.
In general, Dr. Jain said, as a tumor grows, its outer region recruits new blood vessels from surrounding normal tissue. It also forms several abnormal blood vessels of its own. As the tumor grows in a confined space, many of the twisted blood vessels near its center are crushed. In turn, the tumor cells near them appear to die, although they grow into active cancer if transplanted in other animals. High pressures build up in these necrotic regions. Both blood vessels and liquid plasma in the interstitial spaces are squeezed. The pressure, therefore, prevents blood-borne molecules, including oxygen, from entering the central tumor areas.
Pressure is not uniform in normal tissue, Dr. Jain said, so a large molecule such as an antibody would reach its target through convection induced by pressure differences. But in the center of a tumor, pressure is uniformly high, blocking convection.
Molecules also migrate by diffusion Dr. Jain said, which is similar to the way a drop of ink spreads in water.
But he indicated that he measured antibody diffusion in tumors and found that it can take days, weeks or months for such large molecules to reach uniform concentration by diffusion in tumors. By then, it may be too late for treatments to do any good.
Finally, the fluid that builds up in the interstitium slowly leaks out of the tumor, he said, washing away molecules trying to reach its center.
In our Canadian Patent Application Serial Number 568,512 we disclose a new formulation suitable for use for treating cancer (for use in conjunction with at least thermotherapy (hyperthermia) and if desired, other modalities (such as chemotherapy or radiation)), the formulation comprising (for example in a pharmaceutically acceptable carrier): glucose transport protein (active transpo
REFERENCES:
patent: 2583096 (1952-01-01), Hadidian et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4272522 (1981-06-01), Balazs
patent: 4303676 (1981-12-01), Balazs
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), LeVeen et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4795741 (1989-01-01), Leschiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853226 (1989-08-01), Machida et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4946870 (1990-08-01), Partain, III et al.
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4965353 (1990-10-01), della Valle et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5166331 (1992-11-01), della Valle et al.
Balezs E.A. et al, "Hyaluronic acid: Its structure and use", Cosmetics & Toiletries, Polymers in Cosmetics 1984; 99: 65-72.
Camber O. et al, "Diffusion of some low molecular weight compounds in sodium hyaluronate", Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
Camber O. et al, "Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits", Current Eve Research 1987: 6(6): 779-784.
Chang S-C, "Prodrug and vehicle approaches to improve the therapeutic index of topically applied timolol in the pigmented rabbit", Dissertation Abstracts International 1988; 49(2): 367-B.
Cravioto R O et al, Effects of Precipitates Formed by Insulin with Hyaluronic Acid and Mucoid from Vitreous Humor in Depressing Blood-Sugar Levels Science (1950); vol. 111: 520-521.
Gieldanowski J et al, "Studies on immunosuppressive and anti-inflammatory effects of adriamycin", Arch. Immunol. Ther. Exp. (1980); 28(3): 439-446.
Hassan, H.G., et al., "Effects of adjuvants to local anaesthetics on their duration", Acta Anaesthesiol Scand 1985; 29: 384-388.
Hurd, E.R., "Immunosuppressive and antiinflammatory properties of cyclophosphamide, azathioprine and methotrexate", Arthritis and Rheumatism (1973 Jan./Feb.); 16(1): 84-88.
Idson B, "Polymers in skin cosmetics", Cosmetics & Toiletries 1988; 103: 63-68.
Johansson A. et al, "Effects of adjuvants to local anaesthetics on their duration", Acta Anaesthesiol Scand 1985; 29: 736-738.
Kalbhen D.A., "The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon.RTM.)", Z. Rheumatol (1982): 41: 202-211.
Katsu M. et al., "Significance and clinical use of non-steroid anti-inflammatory drugs as substitutes for steroids in steroid dependence", Nippon Rinsho (Jan. 1986) 26(1): 89-95.
Kreis H et al, "Nonsteroid antiinflammatory agents as a substitute treatment for steroids in ATGAM-treated cadaver kidney recipients" Transplantation (Feb. 1984); 37(2): 139-145.
McIlwraith W, "Current concepts in equine degenerative joint disease", Journal of the Am. Veterinary Medical Assoc., 1982; Feb. 1. vol. 180: 239-250.
Mizushima Y., "Possibility of non-steroid anti-inflammatory drugs as a substitute for steroids-analysis of the present situation and demands for the future", Nippon Rinsho (Jan. 1986); 26(1): 61-65.
Nizolek D.J.H. et al, "Corticosteroid and hyaluronic acid treatments in equine degerative joint disease: A Review" The Cornell Veterinarian 1981: 71(4): 355-375.
Pigman W et al, "Acide hyaluronique et facteurs de permeabilite tissulaire" Bull. Soc. Chim. Biol. 1963; 45(2-3): 185-202.
Pruett RC, et al, "Hyaluronic acid vitreious substitute", In: Vitreous Surgery and Advances in Fundus Diagnosis and Tre
Asculai Samuel S.
Falk Rudolf Edgar
Fonda Kathleen K.
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
Sarkis Marcelo K.
LandOfFree
Use of hyaluronic acid or its derivatives to enhance delivery of does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of hyaluronic acid or its derivatives to enhance delivery of, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hyaluronic acid or its derivatives to enhance delivery of will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1910501